Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

A Phase I Dose Finding Trial of MB-CART20.1 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nadine Kutsch, Philipp Gödel, Udo Holtick, Anja Lohneis, Vladan Vucinic, Florentine Pia Altefrohne, Christin Schubert, Sandra Karitzky, Linda Hanssens, Mario Assenmacher, Iris Bürger, Murat Aktas, Peter Borchmann

Blood (2022) 140 (Supplement 1): 12980–12981.

https://doi.org/10.1182/blood-2022-168730

Published: 2022

Journal Articles

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Andreas Mackensen, Linda Hanssens, Matthias Stelljes, Wolfgang A Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner, Alisa Yakushina, Sandra Karitzky, Silke Holtkamp, Mario Assenmacher, Marion Jurk, Georg Rauser, Dina Schneider, Claudia Rossig

Blood (2021) 138 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2021-152452

Published: 2021

Journal Articles

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

Blood (2018) 132 (Supplement 1): 604.

https://doi.org/10.1182/blood-2018-99-110124

Published: 2018

Journal Articles

First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning

Wolfgang Bethge, MD, Stephan Mielke, MD, Dietger Niederwieser, MD, Roland Meisel, MD, Donald w. Bunjes, MD, Arne Brecht, MD, Jurgen Kuball, MD, Sandra Karitzky, PhD, Silke Holtkamp, Christiane Siewert, PhD, Stefanie Pflitsch, Michael Schumm, DVM, Matthias K. Eyrich, MD, Vladan Vucinic, Markus Wiesneth, MD, Kasper Westinga, Rupert Handgretinger, MD PhD

Blood (2017) 130 (Supplement 1): 213.

https://doi.org/10.1182/blood.V130.Suppl_1.213.213

Published: 2017

Journal Articles

Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial

Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD PhD, Sandra Karitzky, PhD, Silke Holtkamp, Christiane Siewert, PhD, Stefanie Pflitsch, Michael Schumm, DVM, Matthias K. Eyrich, MD, Markus Wiesneth, MD, Halvard Bonig, MD MA, Rupert Handgretinger, MD PhD

Blood (2017) 130 (Supplement 1): 214.

https://doi.org/10.1182/blood.V130.Suppl_1.214.214

Published: 2017

Journal Articles

TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial

Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD, Sandra Karitzky, PhD, Silke Holtkamp, PhD, Christiane Siewert, PhD, Michael Schumm, VMD, Matthias K. Eyrich, MD, Markus Wiesneth, Halvard Bönig, MD, Rupert Handgretinger, MD

Blood (2016) 128 (22): 389.

https://doi.org/10.1182/blood.V128.22.389.389

Published: 2016

Journal Articles

Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial

Michael Schumm, VMD, Matthias K. Eyrich, MD, Markus Wiesneth, Halvard Bönig, MD, Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD, Murat Aktas, Philipp Dresing, PhD, Sandra Karitzky, PhD, Silke Holtkamp, PhD, Rupert Handgretinger, MD

Blood (2016) 128 (22): 2172.

https://doi.org/10.1182/blood.V128.22.2172.2172

Published: 2016

Journal Articles

Use of Dendritic Cells Versus Peripheral Blood Lymphocytes To Segregate Alloreactive and Regulatory T Cells during Allogeneic Transplantation.

Tami Katz, PhD, Irit Avivi, MD, Dina Stroopinski, Anna Oliven, Tsila Zuckerman, MD, Sandra Karitzky, PhD, Guy Moeneclaey, PhD, Baldev Vasir, PhD, Jacalyn Rosenblatt, MD, Corrie Lenahan, MD, Jacob M. Rowe, MD, David Avigan, MD

Blood (2005) 106 (11): 5244.

https://doi.org/10.1182/blood.V106.11.5244.5244

Published: 2005

NARROW

A Phase I Dose Finding Trial of MB-CART20.1 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning

Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial

TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial

Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial

Use of Dendritic Cells Versus Peripheral Blood Lymphocytes To Segregate Alloreactive and Regulatory T Cells during Allogeneic Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only